Literature DB >> 25814530

B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality.

Rachelle G Veenstra1, Ryan Flynn1, Katharina Kreymborg2, Cameron McDonald-Hyman1, Asim Saha1, Patricia A Taylor1, Mark J Osborn1, Angela Panoskaltsis-Mortari1, Annette Schmitt-Graeff3, Elisabeth Lieberknecht4, William J Murphy5, Jonathan S Serody6, David H Munn7, Gordon J Freeman8, James P Allison9, Tak W Mak10, Marcel van den Brink2, Robert Zeiser4, Bruce R Blazar1.   

Abstract

Members of the B7 family have been shown to be important for regulating immune responses by providing either positive or negative costimulatory signals. The function of B7-H3 has been controversial. We show that B7-H3 is upregulated in graft-versus-host disease (GVHD) target organs, including the colon, liver, and lung. Infusion of allogeneic donor T cells into B7-H3(-/-) vs wild-type (WT) recipients resulted in increased GVHD lethality associated with increased T-cell proliferation, colonic inflammatory cytokines, and destruction of epithelial barriers. Allogeneic B7-H3(-/-) vs WT donor T cells also had increased T-cell proliferation and GVHD lethality associated with increased proliferation and cytokine secretion in the spleen, intraepithelial lymphocyte inflammatory cytokines, and intestinal permeability. Both resting and activated regulatory T cells (Tregs) lack B7-H3 messenger RNA. Consistent with these data, GVHD was augmented in recipients of B7-H3(-/-) Treg-depleted grafts. In two delayed lymphocyte infusion (DLI) models, T cells lacking B7-H3 are capable of providing graft-versus-leukemia (GVL) effects. We conclude that B7-H3 is responsible for providing a negative costimulatory signal. Our studies provide support for developing and testing new therapies directed toward the B7-H3 pathway, including approaches to augment host B7-H3 early after bone marrow transplantation to prevent GVHD and to develop potent antagonistic antibodies later after transplant to facilitate DLI-mediated GVL without GVHD complications.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25814530      PMCID: PMC4440885          DOI: 10.1182/blood-2014-09-603357

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses.

Authors:  Takuya Ueno; Melissa Y Yeung; Martina McGrath; Sunmi Yang; Nadia Zaman; Benjamin Snawder; Robert F Padera; Ciara N Magee; Rostic Gorbatov; Masaaki Hashiguchi; Miyuki Azuma; Gordon J Freeman; Mohamed H Sayegh; Nader Najafian
Journal:  Eur J Immunol       Date:  2012-09       Impact factor: 5.532

2.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

Authors:  Patricia A Taylor; Christopher J Lees; Bruce R Blazar
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

3.  B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.

Authors:  A I Chapoval; J Ni; J S Lau; R A Wilcox; D B Flies; D Liu; H Dong; G L Sica; G Zhu; K Tamada; L Chen
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

4.  The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease.

Authors:  Y Kataoka; T Iwasaki; T Kuroiwa; Y Seto; N Iwata; N Hashimoto; A Ogata; T Hamano; E Kakishita
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

5.  Early intestinal Th1 inflammation and mucosal T cell recruitment during acute graft-versus-host reaction.

Authors:  D Snider; H Liang
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

6.  Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells.

Authors:  Rachelle G Veenstra; Patricia A Taylor; Qing Zhou; Angela Panoskaltsis-Mortari; Mitsuomi Hirashima; Ryan Flynn; Derek Liu; Ana C Anderson; Terry B Strom; Vijay K Kuchroo; Bruce R Blazar
Journal:  Blood       Date:  2012-06-07       Impact factor: 22.113

7.  LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease.

Authors:  Aleksandra Petrovic; Onder Alpdogan; Lucy M Willis; Jeffrey M Eng; Andrew S Greenberg; Barry J Kappel; Chen Liu; George J Murphy; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

8.  Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Authors:  Bruce R Blazar; Beatriz M Carreno; Angela Panoskaltsis-Mortari; Laura Carter; Yoshiko Iwai; Hideo Yagita; Hiroyuki Nishimura; Patricia A Taylor
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

9.  The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses.

Authors:  Woong-Kyung Suh; Beata U Gajewska; Hitoshi Okada; Matthew A Gronski; Edward M Bertram; Wojciech Dawicki; Gordon S Duncan; Jacob Bukczynski; Suzanne Plyte; Andrew Elia; Andrew Wakeham; Annick Itie; Stephen Chung; Joan Da Costa; Sudha Arya; Tom Horan; Pauline Campbell; Kevin Gaida; Pamela S Ohashi; Tania H Watts; Steven K Yoshinaga; Mark R Bray; Manel Jordana; Tak W Mak
Journal:  Nat Immunol       Date:  2003-08-17       Impact factor: 25.606

10.  Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.

Authors:  Asim Saha; Kazutoshi Aoyama; Patricia A Taylor; Brent H Koehn; Rachelle G Veenstra; Angela Panoskaltsis-Mortari; David H Munn; William J Murphy; Miyuki Azuma; Hideo Yagita; Brian T Fife; Mohammed H Sayegh; Nader Najafian; Gerard Socie; Rafi Ahmed; Gordon J Freeman; Arlene H Sharpe; Bruce R Blazar
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

View more
  28 in total

1.  Role of B7H3/IL-33 Signaling in Pulmonary Fibrosis-induced Profibrogenic Alterations in Bone Marrow.

Authors:  Taku Nakashima; Tianju Liu; Biao Hu; Zhe Wu; Matthew Ullenbruch; Keitaro Omori; Lin Ding; Noboru Hattori; Sem H Phan
Journal:  Am J Respir Crit Care Med       Date:  2019-10-15       Impact factor: 21.405

Review 2.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  Cancer Treat Rev       Date:  2017-06-01       Impact factor: 12.111

Review 3.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

4.  Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.

Authors:  Asim Saha; Patricia A Taylor; Christopher J Lees; Angela Panoskaltsis-Mortari; Mark J Osborn; Colby J Feser; Govindarajan Thangavelu; Wolfgang Melchinger; Yosef Refaeli; Geoffrey R Hill; David H Munn; William J Murphy; Jonathan S Serody; Ivan Maillard; Katharina Kreymborg; Marcel van den Brink; Chen Dong; Shuyu Huang; Xingxing Zang; James P Allison; Robert Zeiser; Bruce R Blazar
Journal:  JCI Insight       Date:  2019-10-03

5.  Wharton's Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro.

Authors:  Tiziana Corsello; Giandomenico Amico; Simona Corrao; Rita Anzalone; Francesca Timoneri; Melania Lo Iacono; Eleonora Russo; Giovanni Francesco Spatola; Maria Laura Uzzo; Mario Giuffrè; Martin Caprnda; Peter Kubatka; Peter Kruzliak; Pier Giulio Conaldi; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

6.  Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.

Authors:  Hongwei Du; Koichi Hirabayashi; Sarah Ahn; Nancy Porterfield Kren; Stephanie Ann Montgomery; Xinhui Wang; Karthik Tiruthani; Bhalchandra Mirlekar; Daniel Michaud; Kevin Greene; Silvia Gabriela Herrera; Yang Xu; Chuang Sun; Yuhui Chen; Xingcong Ma; Cristina Rosa Ferrone; Yuliya Pylayeva-Gupta; Jen Jen Yeh; Rihe Liu; Barbara Savoldo; Soldano Ferrone; Gianpietro Dotti
Journal:  Cancer Cell       Date:  2019-02-11       Impact factor: 31.743

Review 7.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 8.  Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.

Authors:  Leslie S Kean; Laurence A Turka; Bruce R Blazar
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

9.  Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.

Authors:  Elodie Picarda; Kim C Ohaegbulam; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2016-05-20       Impact factor: 12.531

Review 10.  Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

Authors:  Amer Assal; Justin Kaner; Gopichand Pendurti; Xingxing Zang
Journal:  Immunotherapy       Date:  2015-11-16       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.